tomography scans of the chest and abdomen are usually obtained that provide information with regard to the primary tumor, the presence of regional nodal metastasis, or the existence of distant visceral metastasis. Endoscopic ultrasonography is used commonly as a staging modality because it seems to complement the information provided by computed tomography, especially in terms of primary tumor staging accuracy and of regional nodal staging. The current staging system in use for esophageal malignancies is the TNM classification designated by the American Joint Committee in Cancer. Tumor stage provides prognostic information and helps to determine the treatment modalities to be used in a specific case as well as their intent (curative or palliative). Unfortunately, clinical staging remains rather imprecise, thus representing a major problem when trying to allocate and/or compare treatment modalities for patients with esophageal malignancies.
The case offered in this report describes a common presentation of esophageal cancer. Cancer of the esophagus may occur in both genders, with the median age of onset in the mid 60s. As was mentioned previously, the most common presenting symptom is progressive dysphagia. Adenocarcinomas of the esophagus may initially develop submucosally and may on occasion be missed on initial endoscopic evaluation and imaging studies. The finding on esophageal ultrasound of &dquo;a mass in the distal esophagus into the proximal stomach with transmural infiltration and regional lymphadenopathy&dquo; is consistent with the concept that once symptoms (dysphagia) are present, there is a high likelihood that the disease process is at least regionally advanced. The pathological diagnosis of an adenocarcinoma is consistent with the current histological trend, with adenocarcinoma presently being the most common histological type in the Western world. The location of the primary tumor in the gastroesophageal junction is also typical for adenocarcinoma.
Chemotherapy, radiation therapy, and surgical resection are commonly used singly or in combination in the management of esophageal tumors. The aggressiveness of the therapeutic approach that is ultimately chosen is predicated on the perceived likelihood of achieving a cure. Patients' and physicians' preferences also guide treatment choice. Surgical resection continues to play a significant role in the management of esophageal malignancies and is regarded as a standard therapeutic option for selected patients with stage III tumors, particularly those with T3 lesions. The overall results of surgical resection remain relatively poor; in addition, operative morbidity and mortality are not insignificant with the most commonly used surgical techniques (transhiatal resection vs.
abdominal stomach mobilization with transthoracic esophageal resection). Given these results, new therapeutic modalities have been investigated in recent decades that have used radiation therapy singly or in combination with chemotherapy. Current evidence suggests that combined chemoradiotherapy is superior to radiation therapy alone and currently represents the therapeutic standard for the definitive treatment of nonresectable regional disease. Although locoregional control is quite reasonable with these noninvasive combined approaches, the results in tumor has arisen in the cells lining the stomach and is thus classified as an adenocarcinoma. Tumors occurring in the gastroesophageal junction are usually of the adenocarcinoma type.
Treatment for esophageal tumors comprises surgery, radiation therapy, and chemotherapy. Although the ideal treatment for a fully respectable tumor would be surgery only, neoadjuvant chemoradiation therapy is usually given prior to surgery, particularly in patients with positive lymph nodes. In neoadjuvant therapy, the chemotherapy acts as a radiosensitizer, and the combination of both treatments usually debulks the tumor prior to surgery, making successful resection more likely. In some cases, surgery is performed first and chemoradiation is given postoperatively, but the choice of chemoradiation prior to surgery was made in this case and appears appropriate.
Prognosis for a patient with a tumor of this type depends, of course, on staging. The presence of positive lymph nodes increases the possibility of recurrence. A local recurrence is one possibility, but such tumors often metastasize to the liver or lung. In the case of metastatic disease in the liver or lung, palliative chemotherapy protocols are available, although they do not generally result in long-term control. Drug combinations could be used for palliative treatment: FAM (5-FU, leucovorin, Adriamycin@, and mitomycin) and ELF (etoposide, leucovorin, and 5-FU) are possibilities. Treatment with docetaxel or gemcitabine is also an option in the palliative situation. Bone metastases are less common than liver or lung metastases, but they do occur. In the case of painful bone metastases, radiation therapy can be given for palliation. Deva Nathan, MD OLR Cancer Center 3800 North Central Chicago, IL 60634 Naturopathic Medicine Analysis Naturopathic medicine, sometimes called naturopathy, is a distinct system of primary care based on the principles of prevention, removal of the cause of disease, support for the healing power of the body, and treatment modalities based on state-of-the-art scientific research. Naturopathic physicians who complete 4 years of naturopathic medical school receive Doctor of Naturopathy (ND) degree and are eligible to take national board exams in order to become licensed in various states. Naturopathic practice includes functional nutrition, botanical medicine, homeopathy, hydrotherapy, and naturopathic manipulation. Naturopathic recommendations for the care of a patient with cancer either before chemotherapy, radiation, or surgery, or after chemotherapy, radiation or surgery, involve a complementary approach with the patient's oncologist. During chemotherapy, various supplements have been found to decrease the toxicity and enhance the effectiveness of specific chemotherapeutic agents. Specifically in this case, the patient would have benefited with the use of glutamine,' milk thistle (silyloum marianum), Cool 0, and vitamins C and E'' j to help decrease the toxicity brought on by 5-FU. The possible side effects of nephrotoxicity brought on by cisplatin can be decreased through the use of CoQ10 and silymarin,' I whereas ginkgo biloba can help to increase peripheral blood flow and thus decrease possible neurotoxicity. With a decrease in side effects, this patient may have been able to finish chemotherapy. In addition, certain supplements can help support normal tissue repair from radiation therapy (i.e., glutamine), provided the patient does not have excessive nephrotoxicity. Preparation and immediate healing after surgery can be complemented by homeopathic arnica, bromelain (anti-inflammatory), zinc, gambir (an herb), and other antioxidants.
A naturopathic approach to the patient, who has already had chemotherapy, radiation, and an Ivor Lewis esophagogastrectomy for adenocarcinoma of the gastroesophageal junction and adenocarcinoma in situ of the stomach, necessitates more extensive clarification of information. At the beginning of the case, as a naturopathic practitioner, my approach would be to determine whether she has any gastric function left. Assuming that she started on Zoloft~, Priloseco, Pepcid AC°, and atenolol during chemotherapy and that all of her symptoms-shortness of breath with exertion, belching, avoiding hard-crust foods, trembling in extremities, fatigue, and hair texture-began after surgery, one needs to question her ability to digest and absorb nutrients. In addition, further data are needed on complete blood chemistry values, especially liver and kidney function, both before and after chemotherapy. As a naturopathic practitioner, I am concerned with patterns that can be found based on where normal chemistry values lie on a continuum. Blood urea nitrogen, serum creatinine, calcium, magnesium, and phosphorus, in addition to a thyroid panel with a serum transferrin and body mass index, would be of benefit. In addition, I would evaluate whether the patient was truly hyperchlorhydric before and after chemotherapy, radiation, and surgery (necessitating her medications of Prilosec&reg; and Pepcid AC&reg;). Depending on specifics to her surgery,
